Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September
Oxurion to Host Conference Call following the H1 Financial Results
Leuven,
Following the announcement, Oxurion’s management will host a conference call in English on
Oxurion’s First Half 2020 Conference Call & Webcast Details:
Date:
Time:
Participant telephone numbers:
Belgium Toll Free: 0800 746 68
Standard International Access: +44 (0) 20 3003 2666
Password:
There will be a live listen-only webcast of the event, accessible from the
https://www.oxurion.com/news-events
An on-demand version of the event will also be made available shortly after the event has finished.
END
For further information please contact:
Global Head of Investor Relations & Corporate Communications Tel: +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com | Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com |
About
- THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Phase 1 results for the treatment of DME. The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
THR-149 was developed in conjunction with
- THR-687, is a pan-RGD integrin inhibitor, that is initially being developed as a potential new standard of care for all DME patients. Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in
January 2020 . THR-687 is expected to enter a Phase 2 clinical trial by mid-2021.
THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos NV (Euronext & NASDAQ: GLPG).
More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
© OMX, source